% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Neukirch:303025,
      author       = {L. Neukirch$^*$ and S. Uhrig-Schmidt$^*$ and K. von
                      Werthern$^*$ and A. Tuch$^*$ and J. A. Kraske and Y. Lyu$^*$
                      and B. Lenoir$^*$ and S. Eichmüller$^*$ and M. Meyer$^*$
                      and I. Zörnig and D. Jäger$^*$ and P. Schmidt$^*$},
      title        = {{N}eo-antigen tumor vaccination depends on {CD}4-licensing
                      conveyed by adeno-associated virus like particles.},
      journal      = {Molecular therapy},
      volume       = {nn},
      issn         = {1525-0016},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01472},
      pages        = {nn},
      year         = {2025},
      note         = {#EA:D120#LA:D210# / epub},
      abstract     = {Personalized treatment has become a realistic option for
                      tumor patients, accelerated by significantly reduced
                      sequencing costs of tumor genomes and advances in vaccine
                      formulations. The druggability of cancer neo-antigens caused
                      by individual mutations is centered in this effort. We here
                      use an AAV-based VLP platform to compose a neo-antigen
                      specific protein vaccine that is effective in a murine
                      prevention and treatment setting. Furthermore, we show that
                      CD4+ T cell responses that are provided by the AAV capsid
                      are crucial for an effective murine melanoma treatment. To
                      uncover the optimal composition of a peptide vaccine we
                      de-linked MHC-II helper peptides from the capsid and
                      formulated an efficient neo-antigen specific vaccine, which
                      showed the independence of CD4+ T cell response from tumor
                      sequences. The findings are supported by clinical data of
                      neo-antigen vaccinated tumor patients. Our results punctuate
                      on the significance of MHC-II epitopes for CD8+ T cell
                      responses and suggest a future use of AAVLPs as neo-epitope
                      vaccines in personalized cancer treatments.},
      cin          = {D120 / D210},
      ddc          = {610},
      cid          = {I:(DE-He78)D120-20160331 / I:(DE-He78)D210-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40671675},
      doi          = {10.1016/j.ymthe.2025.07.014},
      url          = {https://inrepo02.dkfz.de/record/303025},
}